Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update.
Investors and the public can access the live webcast through a dedicated link, and a replay will remain available for at least 30 days on the company's investor relations website.
Krystal Biotech (NASDAQ: KRYS), un'azienda biotecnologica in fase commerciale, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 6 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una teleconferenza e una diretta web alle 8:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sulle attività.
Investitori e pubblico potranno accedere alla diretta streaming tramite un link dedicato, e la registrazione resterà disponibile per almeno 30 giorni sul sito web dedicato agli investitori della società.
Krystal Biotech (NASDAQ: KRYS), una empresa biotecnológica en fase comercial, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 6 de mayo de 2025, antes de la apertura de los mercados estadounidenses. La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 am ET el mismo día para discutir los resultados y ofrecer una actualización comercial.
Los inversores y el público podrán acceder a la transmisión en vivo a través de un enlace dedicado, y la repetición estará disponible durante al menos 30 días en el sitio web de relaciones con inversores de la empresa.
Krystal Biotech (NASDAQ: KRYS)는 상업 단계에 있는 생명공학 회사로, 2025년 5월 6일 화요일 미국 시장 개장 전에 2025년 1분기 재무실적 발표를 예정하고 있습니다. 회사는 같은 날 동부 표준시 기준 오전 8시 30분에 실적 발표와 사업 현황 업데이트를 위한 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
투자자와 일반 대중은 전용 링크를 통해 생중계에 접속할 수 있으며, 녹화된 영상은 회사 투자자 관계 웹사이트에서 최소 30일간 다시보기로 제공됩니다.
Krystal Biotech (NASDAQ : KRYS), une entreprise biotechnologique en phase commerciale, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 6 mai 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et une webdiffusion à 8h30 ET le même jour pour discuter des résultats et fournir une mise à jour commerciale.
Les investisseurs et le public pourront accéder à la diffusion en direct via un lien dédié, et un replay restera disponible pendant au moins 30 jours sur le site des relations investisseurs de l'entreprise.
Krystal Biotech (NASDAQ: KRYS), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 6. Mai 2025, vor Öffnung der US-Märkte, terminiert. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Investoren und die Öffentlichkeit können den Live-Webcast über einen speziellen Link verfolgen, und eine Aufzeichnung wird für mindestens 30 Tage auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52291.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) release Q1 2025 earnings?
How can investors access Krystal Biotech's Q1 2025 earnings call?
Will there be a replay available for Krystal Biotech's Q1 2025 earnings call?
What time is Krystal Biotech's Q1 2025 earnings conference call?
